Patent Grant
11571293
This disclosure relates generally to implantable optical devices. More specifically, this disclosure relates to an intraocular pseudophakic contact lens with a mechanism for securing by an anterior leaflet of a capsular wall and a related system and method.
In a normal human eye, light enters through the cornea and passes through the pupil, and the natural crystalline lens focuses the light onto the retina of the eye. However, due to cataracts or other problems, the natural crystalline lens of an eye may need to be replaced with an artificial intraocular lens (IOL). The term “pseudophakia” is used to describe an eye in which the natural crystalline lens has been replaced with an intraocular lens.
Before an intraocular lens is placed into a patient's eye, a doctor or other personnel typically selects an intraocular lens that is designed to provide desired refractive correction for the patient's eye. For example, an intraocular lens could have an optical lens designed to correct myopia (near-sightedness), hyperopia (far-sightedness), astigmatism, or other refractive errors that occur naturally in the patient's eye. However, it is often the case that the intraocular lens selected for a patient's eye does not fully correct (and may even cause) some form of refractive error in the patient's eye. This refractive error is referred to as “residual” refractive error.
There are various conventional options for correcting residual refractive error, all of which have their disadvantages. For example, one intraocular lens in a patient's eye could be replaced with a different intraocular lens, but this typically has a high risk of surgical complications. Ablation surgery (such as LASIK) on the cornea of a patient's eye could be done to correct residual refractive error, but this can have a high level of unwanted side effects, particularly for older patients. An additional intraocular lens (often referred to as a “piggyback” IOL) could be inserted in front of an existing intraocular lens, but this is typically an invasive procedure with less predictability associated with the final refractive outcome. In addition, intracorneal lenses (ICLs) can be inserted into the cornea of a patient's eye, but this is often more invasive and has a high degree of rejection. In general, the above procedures are typically not predictable and have a higher degree of surgical risk. Also, the devices used in the above procedures are difficult to remove and “reverse” any residual refractive error, resulting in a higher risk of leaving the patient with induced visual aberration.
This disclosure provides an intraocular pseudophakic contact lens with a mechanism for securing by an anterior leaflet of a capsular wall and a related system and method.
In a first embodiment, an apparatus includes an intraocular pseudophakic contact lens having an optical lens and haptics extending radially from the optical lens and configured to be inserted under an anterior leaflet of a capsular wall in an eye in order to capture and confine the haptics under the anterior leaflet. Anterior surfaces of the haptics include capsular wall-engaging surfaces configured to contact an inner capsular wall surface at the anterior leaflet, where the capsular wall-engaging surfaces are configured to promote confinement, capture, or attachment of the haptics. Posterior surfaces of the haptics include ridges configured to capture at least one edge of an artificial intraocular lens in order to secure the intraocular pseudophakic contact lens to the artificial intraocular lens.
In a second embodiment, a system includes an artificial intraocular lens having a first optical lens and first haptics configured to be implanted within a capsular bag in an eye. The system also includes an intraocular pseudophakic contact lens having a second optical lens and second haptics extending radially from the second optical lens and configured to be inserted under an anterior leaflet of a capsular wall in the eye in order to capture and confine the second haptics under the anterior leaflet. Anterior surfaces of the second haptics include capsular wall-engaging surfaces configured to contact an inner capsular wall surface at the anterior leaflet, where the capsular wall-engaging surfaces are configured to promote confinement, capture, or attachment of the second haptics. Posterior surfaces of the second haptics include ridges configured to capture at least one edge of the artificial intraocular lens in order to secure the intraocular pseudophakic contact lens to the artificial intraocular lens.
In a third embodiment, an apparatus includes an intraocular pseudophakic contact lens having an optical lens and haptics extending radially from the optical lens and configured to be inserted under an anterior leaflet of a capsular wall in an eye in order to capture and confine the haptics under the anterior leaflet. Anterior surfaces of the haptics include capsular wall-engaging surfaces configured to contact an inner capsular wall surface at the anterior leaflet, where the capsular wall-engaging surfaces are configured to promote confinement, capture, or attachment of the haptics. Posterior surfaces of the haptics include ridges configured to capture at least one edge of an artificial intraocular lens in order to secure the intraocular pseudophakic contact lens to the artificial intraocular lens. The ridge of each haptic includes a lip projecting from the ridge and extending inward from the ridge. The optical lens is positioned above the anterior and posterior surfaces of the haptics such that the anterior and posterior surfaces of the haptics are positioned below at least part of a posterior surface of the optical lens. The intraocular pseudophakic contact lens includes at least three haptics.
Other technical features may be readily apparent to one skilled in the art from the following figures, descriptions, and claims.
For a more complete understanding of this disclosure and its features, reference is now made to the following description, taken in conjunction with the accompanying drawings, in which:
This disclosure provides various intraocular pseudophakic contact lenses (IOPCLs) that can be used in conjunction with intraocular lenses (IOLs). An intraocular pseudophakic contact lens generally represents a contact lens-type device that can be implanted within a patient's eye and placed on the anterior surface of an intraocular lens in the patient's eye. In some embodiments, the intraocular pseudophakic contact lens substantially corrects residual refractive error present after implantation of the intraocular lens, such as after a lensectomy (cataract) procedure. In other embodiments, the intraocular pseudophakic contact lens provides some other form of vision correction when placed on the intraocular lens in the patient's eye. In addition, the intraocular pseudophakic contact lens includes haptics or other mechanisms allowing the intraocular pseudophakic contact lens to be confined/captured by the anterior leaflet of the capsular wall in the patient's eye. In some instances, the haptics or other mechanisms can actually attach to the anterior leaflet of the capsular wall, such as through fibrosis during the healing process, to help to secure the intraocular pseudophakic contact lens in place.
Unlike conventional approaches, an intraocular pseudophakic contact lens can be implanted with less surgical risk. Moreover, an intraocular pseudophakic contact lens allows a patient to see immediately after implantation of the intraocular pseudophakic contact lens. Further, an intraocular pseudophakic contact lens can be easily replaced if a different lens is needed, such as to correct residual refractive error or to provide some other form of vision correction, or even removed if necessary. In addition, with techniques such as intraoperative wavefront aberrometry now available, refractive outcome can be measured during the actual procedure in which an intraocular pseudophakic contact lens is being implanted, which helps to identify immediately that a desired refractive target is obtained.
As shown in
The optical lens 102 can be formed from any suitable material(s), such as silicone or acrylic. The optical lens 102 can also be formed in any suitable manner, such as by using a mold or lathe cut manufacturing process. Different lenses 102 can be designed and manufactured to provide a wide range of diopters, and each optical lens 102 can be designed to correct any suitable refractive error(s) or provide other suitable vision correction. Example types of refractive errors that can be corrected include myopia, hyperopia, and astigmatism.
The optical lens 102 in this example has a convex top surface and a concave bottom surface. However, the optical lens 102 can have any other suitable shape, which could depend (at least in part) on the type of refractive error(s) being corrected or other vision correction being made. As particular examples, the optical lens 102 could be convex, concave, spherical, aspherical, toric, mono-focal, or multi-focal. The specific lens platform used as the optical lens 102 in the intraocular pseudophakic contact lens 100 can be selected to provide the desired refractive correction or other vision correction in a patient's eye. The optical lens 102 could also include various other features as needed or desired, such as when the optical lens 102 is weighted (like at its bottom) so that the optical lens 102 orients itself on an intraocular lens in a desired orientation (like for toric platforms) or when the optical lens 102 is tinted, is photochromic, or includes an ultraviolet (UV) absorber.
Multiple haptics 104a-104b extend from multiple sides of the optical lens 102. The haptics 104a-104b are sized and shaped so that they extend a short distance from the optical lens 102 and fit under the anterior leaflet of the capsular wall in a patient's eye after implantation. Each haptic 104a-104b could be formed from any suitable material(s) and in any suitable manner. For example, each haptic 104a-104b could be formed from the same material(s) as the optical lens 102. Note that while two haptics 104a-104b are shown here, the intraocular pseudophakic contact lens 100 could include any number of haptics, including a single haptic. Also note that while the haptics 104a-104b angle downward, the haptics 104a-104b could have any other suitable arrangement.
In this example, the haptics 104a-104b are separated from the optical lens 102 by projections or extensions 106 that project from the sides of the optical lens 102. These extensions 106 represents portions of the intraocular pseudophakic contact lens 100 in which ends of the haptics 104a-104b could be embedded. Each extension 106 could be formed from any suitable material(s) and in any suitable manner. For example, each extension 106 could represent a portion of the material(s) forming the optical lens 102 and therefore represent an extension of the optical lens 102 itself. However, this need not be the case. For instance, the optical lens 102 could be placed within a retaining ring that is integral with or attached to the extensions 106, or the extensions 106 could be secured to the optical lens 102 itself using adhesive or other suitable connecting mechanism.
Note that while two extensions 106 are shown here, the intraocular pseudophakic contact lens 100 could include any number of extensions, including a single extension. Also note that the presence of the extensions 106 is not required and that the haptics 104a-104b could be integrated directly with the optical lens 102. In those embodiments, the haptics 104a-104b could represent portions of the material(s) forming the optical lens 102, although this need not be the case. For instance, the optical lens 102 could be placed within a retaining ring that is integral with or attached to the haptics 104a-104b, or the haptics 104a-104b could be secured to the optical lens 102 itself using adhesive or other suitable connecting mechanism.
Each of the haptics 104a-104b includes a textured surface 108, which in this example is formed using various holes formed partially or completely through the haptics 104a-104b. The textured surfaces 108 allow the haptics 104a-104b to be captured and confined by the anterior leaflet of the capsular wall in a patient's pseudophakic eye. In some cases, the textured surfaces 108 allow the haptics 104a-104b to actually physically bond to the anterior leaflet of the capsular wall in the patient's eye, such as through fibrosis during the healing process. The haptics 104a-104b help to secure the intraocular pseudophakic contact lens 100 in place on an intraocular lens. Note that the numbers and sizes of the holes in the textured surfaces 108 are for illustration only and that the haptics 104a-104b could include different numbers and sizes of holes. For instance, the haptics 104a-104b could include a large number of very small holes or other structures forming a texture that promotes confinement, capture, or attachment to the anterior leaflet of the capsular wall.
The anterior leaflet of the capsular wall in a patient's eye is typically created during a capsulotomy in which the natural crystalline lens in the patient's eye is removed and replaced with an intraocular lens. The anterior leaflet represents the outer portion of the front side of the capsular bag that remains after an opening (referred to as a capsulorhexis) is formed in the capsular bag so that the natural crystalline lens can be removed. In some cases, this could occur long before the intraocular pseudophakic contact lens 100 is to be implanted. After the capsulotomy, the anterior leaflet of the capsular wall typically shrinks and undergoes fibrosis during the healing process.
When the intraocular pseudophakic contact lens 100 is inserted into the patient's eye, the intraocular pseudophakic contact lens 100 can be positioned so that the haptics 104a-104b extend under the anterior leaflet in the patient's eye. This allows the haptics 104a-104b to be captured and confined by the anterior leaflet. The haptics 104a-104b could also be physically attached to the anterior leaflet over time, such as by way of a “re-fibrosis” of the anterior leaflet. This re-fibrosis of tissue will bond to and cover part or all of the haptics 104a-104b, further securing the intraocular pseudophakic contact lens 100 in place. Note, however, that the intraocular pseudophakic contact lens 100 could also be implanted during the same procedure in which the intraocular lens is being implanted. In that case, the intraocular pseudophakic contact lens 100 could be secured by the haptics 104a-104b and possibly during fibrosis (and not re-fibrosis) within the patient's eye.
As shown in
The intraocular pseudophakic contact lens 400 also includes one or more pins 410. Each pin 410 projects downward from an extension 406 or from the inner end of a haptic 404a-404b. The pin(s) 410 can be used to pierce the anterior surface of an intraocular lens or to rest on the anterior surface of the intraocular lens. In addition to the capture/confinement of the haptics 404a-404b by the anterior leaflet, the pins 410 can help to further hold the intraocular pseudophakic contact lens 400 in place and resist slipping of the intraocular pseudophakic contact lens 400. In some cases, the pins 410 could be used to prevent movement of the intraocular pseudophakic contact lens 400 during the period immediately after implantation and before the haptics 404a-404b of the intraocular pseudophakic contact lens 400 have bonded to the anterior leaflet of the capsular wall in the patient's eye (such as via fibrosis).
Each pin 410 could be formed from any suitable material(s) and in any suitable manner. Note that while two pins 410 are shown here, the intraocular pseudophakic contact lens 400 could include any number of pins, including a single pin. Also note that while the pins 410 here are shown as having sharp ends, this need not be the case. For example, the pins 410 could have rounded or blunted surfaces to help the pins 410 sit on (without piercing) the anterior surface of an intraocular lens. In addition, while the pins 410 are shown here as extending through or being embedded within the extensions 406, the pins 410 could be located in any other suitable position(s). For instance, the pins 410 could be moved to the outer ends of the haptics 404a-404b, or additional pins 410 could be placed at the outer ends of the haptics 404a-404b.
As noted above, the intraocular pseudophakic contact lens 400 can be implanted during the same procedure in which an intraocular lens is being implanted or during a subsequent procedure after the intraocular lens has already been implanted in a patient's eye. The anterior leaflet of the capsular wall of the patient's eye could be used to capture and confine the haptics 404a-404b of the intraocular pseudophakic contact lens 400 under the anterior leaflet, and optionally fibrosis or re-fibrosis could occur to attach the haptics 404a-404b to the patient's eye. The pins 410 can be used to help hold the intraocular pseudophakic contact lens 400 in place.
As shown in
The intraocular pseudophakic contact lens 600 can be implanted during the same procedure in which an intraocular lens is being implanted or during a subsequent procedure after the intraocular lens has already been implanted in a patient's eye. The anterior leaflet of the capsular wall of the patient's eye could be used to capture and confine the haptics 604a-604b of the intraocular pseudophakic contact lens 600 under the anterior leaflet, and optionally fibrosis or re-fibrosis could occur to attach the haptics 604a-604b to the patient's eye.
As shown in
The intraocular pseudophakic contact lens 900 also includes one or more pins 908. Each pin 908 projects downward from an extension 906 or from the inner end of a haptic 904a-904b. The pin(s) 908 can be used to pierce the anterior surface of an intraocular lens or to rest on the anterior surface of the intraocular lens. In addition to the capture/confinement of the haptics 904a-904b by the anterior leaflet, the pins 908 can help to further hold the intraocular pseudophakic contact lens 900 in place and resist slipping of the intraocular pseudophakic contact lens 900. In some cases, the pins 908 could be used to prevent movement of the intraocular pseudophakic contact lens 900 during the period immediately after implantation and before the haptics 904a-904b of the intraocular pseudophakic contact lens 900 have bonded to the anterior leaflet of the capsular wall in the patient's eye (such as via fibrosis).
Each pin 908 could be formed from any suitable material(s) and in any suitable manner. Note that while two pins 908 are shown here, the intraocular pseudophakic contact lens 900 could include any number of pins, including a single pin. Also note that while the pins 908 here are shown as having sharp ends, this need not be the case. For example, the pins 908 could have rounded or blunted surfaces to help the pins 908 sit on (without piercing) the anterior surface of an intraocular lens. In addition, while the pins 908 are shown here as extending through or being embedded within the extensions 906, the pins 908 could be located in any other suitable position(s). For instance, the pins 908 could be moved to the outer ends of the haptics 904a-904b, or additional pins 908 could be placed at the outer ends of the haptics 904a-904b.
The intraocular pseudophakic contact lens 900 can be implanted during the same procedure in which an intraocular lens is being implanted or during a subsequent procedure after the intraocular lens has already been implanted in a patient's eye. The anterior leaflet of the capsular wall of the patient's eye could be used to capture and confine the haptics 904a-904b of the intraocular pseudophakic contact lens 900 under the anterior leaflet, and optionally fibrosis or re-fibrosis could occur to attach the haptics 904a-904b to the patient's eye. The pins 908 can be used to help hold the intraocular pseudophakic contact lens 900 in place.
As shown in
The intraocular pseudophakic contact lens 1100 also includes one or more pins 1108. Each pin 1108 projects downward from the outer end of a haptic 1104a-1104b. The pins 1108 are therefore positioned farther away from the optical lens 1102 compared to the pins 908. This may allow the intraocular pseudophakic contact lens 1100 to be used with larger intraocular lenses. This may also allow the pins 1108 to extend to or beyond the edges of an intraocular lens, which could help the intraocular pseudophakic contact lens 1100 to lock onto the anterior surface or sides of the intraocular lens or to reduce sliding of the intraocular pseudophakic contact lens 1100 on the intraocular lens.
The intraocular pseudophakic contact lens 1100 can be implanted during the same procedure in which an intraocular lens is being implanted or during a subsequent procedure after the intraocular lens has already been implanted in a patient's eye. The anterior leaflet of the capsular wall of the patient's eye could be used to capture and confine the haptics 1104a-1104b of the intraocular pseudophakic contact lens 1100 under the anterior leaflet, and optionally fibrosis or re-fibrosis could occur to attach the haptics 1104a-1104b to the patient's eye. The pins 1108 can be used to help hold the intraocular pseudophakic contact lens 1100 in place.
In this example, the haptics 1304a-1304c are formed by large projections that extend from the sides of the optical lens 1302, where the projections have a thickness that tapers towards the outer edges of the projections. This facilitates easier insertion of the haptics 1304a-1304c under the anterior leaflet of the capsular wall in a patient's eye. Each of the haptics 1304a-1304c could include a textured surface, such as a number of holes or other structures, that promotes confinement, capture, or attachment to the anterior leaflet of the capsular wall. While three haptics 1304a-1304c are shown here, other numbers of haptics could also be used.
As shown in
In this example, the haptics 1404a-1404b are formed by larger projections that extend from the sides of the optical lens 1402. Each haptic 1404a-1404b includes an inner portion 1406 that is connected to the optical lens 1402 and an outer portion 1408 that is connected to the inner portion 1406, effectively forming long “wings” extending from the optical lens 1402. The outer portions 1408 have a thickness that tapers towards the outer edges of the haptics 1404a-1404b, which facilitates easier insertion of the haptics 1404a-1404b under the anterior leaflet of the capsular wall in a patient's eye. The inner portion 1406 projects outward and downward in this example, while the outer portion 1408 projects outward and slightly upward in this example (although other forms could also be used). This shape allows the haptics 1404a-1404b to be used with larger intraocular lenses while still extending under the anterior leaflet of the capsular wall.
Each of the haptics 1404a-1404b also includes a ridge 1410, and multiple ridges 1410 of multiple haptics 1404a-1404b can be used to capture one or more edges of the underlying intraocular lens. This can help to center the intraocular pseudophakic contact lens 1400 on the intraocular lens. This can also help to retain the intraocular pseudophakic contact lens 1400 in place on the intraocular lens during the healing process.
As shown in
Each of the haptics 1604a-1604b also includes a ridge 1610, and multiple ridges 1610 of multiple haptics 1604a-1604b can be used to capture one or more edges of the underlying intraocular lens. This can help to center the intraocular pseudophakic contact lens 1600 on the intraocular lens. This can also help to retain the intraocular pseudophakic contact lens 1600 in place on the intraocular lens during the healing process.
In addition, the intraocular pseudophakic contact lens 1600 here includes multiple segments 1612 located along the sides of the optical lens 1602. The segments 1612 denote projections from the optical lens 1602, and at least some of the segments 1612 could be coupled to the haptics 1604a-1604b (such as when ends of the haptics 1604a-1604b are embedded in the segments 1612). The segments 1612 extend downward so that the bottom surfaces of the segments 1612 are located below the optical lens 1602. As a result, when implanted into a patient's eye, the segments 1612 keep the optical lens 1602 separated from the underlying intraocular lens. Depending on the shape of the posterior surface of the optical lens 1602 and the shape of the anterior surface of the underlying intraocular lens, this could elevate the optical lens 1602 over an optical lens within the underlying intraocular lens so that the optical lenses do not contact each other.
Each of the segments 1612 could be formed from any suitable material(s) and in any suitable manner. For example, each segment 1612 could represent a portion of the material(s) forming the optical lens 1602 and therefore represent an extension of the optical lens 1602 itself. However, this need not be the case. For instance, the optical lens 1602 could be placed within a retaining ring that is integral with or attached to the segments 1612, or the segments 1612 could be secured to the optical lens 1602 itself using adhesive or other suitable connecting mechanism. Each of the segments 1612 could also have any suitable size, shape, and dimensions. For example, the segments 1612 could be smaller or larger (relative to the other structures) than what is shown in
The ability to space the optical lens 1602 away from the underlying intraocular lens could provide various benefits. For example, elevating the optical lens 1602 over the underlying intraocular lens may allow for an increase in aqueous flow between the anterior surface of the intraocular lens and the posterior surface of the optical lens 1602. An increased flow of aqueous between the lenses could help to reduce lens deposits on either or both of the lenses. Also, the presence of aqueous between the lenses can help to improve the optic or image quality of the combined lens system. In addition, by providing more space between the lenses, the intraocular pseudophakic contact lens 1600 could be used with a wider range of intraocular lenses that have varying anterior curvature surfaces, allowing the intraocular pseudophakic contact lens 1600 to be used with a wider range of intraocular lens models and powers.
As shown in
The haptics 1904a-1904b in this example include thicker outer portions 1908 with larger ridges 1910 compared to the corresponding components of the intraocular pseudophakic contact lens 1600. This allows the haptics 1904a-1904b to be used with even larger intraocular lenses. Moreover, each of the ridges 1910 includes a lip 1911 that can facilitate the capture of the underlying intraocular lens. Each of the lips 1911 denotes any suitable inward projection from the corresponding ridge 1910.
Again, when implanted into a patient's eye, the segments 1912 help to keep the optical lens 1902 separated from the underlying intraocular lens. Depending on the shape of the posterior surface of the optical lens 1902 and the shape of the anterior surface of the underlying intraocular lens, this could elevate the optical lens 1902 over an optical lens within the underlying intraocular lens so that the optical lenses do not contact each other. The ability to space the optical lens 1902 away from the underlying intraocular lens could provide various benefits, such as those described above with respect to the intraocular pseudophakic contact lens 1600.
As shown in
In this example, the haptics 2204a-2204c are formed by large projections that extend from the sides of the optical lens 2202, where the projections have a thickness that tapers towards the outer edges of the projections. This facilitates easier insertion of the haptics 2204a-2204c under the anterior leaflet of the capsular wall in a patient's eye. Each of the haptics 2204a-2204c could include a textured surface, such as a number of holes or other structures, that promotes confinement, capture, or attachment to the anterior leaflet of the capsular wall. While three haptics 2204a-2204c are shown here, other numbers of haptics could also be used. In some embodiments, the haptics 2204a-2204c can be positioned at an even spacing of 120°.
Also in this example, an alignment marking 2212 is provided on one of the haptics 2204b. In this particular example, the alignment marking 2212 represents the letter “R,” although any other suitable marking(s) may be used here in any suitable location(s). The alignment marking 2212 can be used to identify the proper orientation of the intraocular pseudophakic contact lens 2200, such as by identifying the haptic 2204b that is to be positioned on the right side of the intraocular pseudophakic contact lens 2200 (from the perspective of the surgeon or other medical personnel) after implantation.
As shown in
In this example, the haptics 2504a-2504d are formed by large projections that extend from the sides of the optical lens 2502, where the projections have a thickness that tapers towards the outer edges of the projections. This facilitates easier insertion of the haptics 2504a-2504d under the anterior leaflet of the capsular wall in a patient's eye. Each of the haptics 2504a-2504d could include a textured surface, such as a number of holes or other structures, that promotes confinement, capture, or attachment to the anterior leaflet of the capsular wall. While four haptics 2504a-2504d are shown here in two groups on opposite sides of the optical lens 2502, other numbers and arrangements of haptics could also be used.
As shown in
In this example, the haptics 2804 are formed by large projections that extend from the sides of the optical lens 2802, where the projections have a thickness that tapers towards the outer edges of the projections. This facilitates easier insertion of the haptics 2804 under the anterior leaflet of the capsular wall in a patient's eye. Each of the haptics 2804 could include a textured surface, such as a number of holes or other structures, that promotes confinement, capture, or attachment to the anterior leaflet of the capsular wall. While three haptics 2804 are shown here, other numbers and arrangements of haptics could also be used.
In this example, the optical lens 2802 of the intraocular pseudophakic contact lens 2800 includes a first lens portion 2812 and a second lens portion 2814. The two portions 2812-2814 of the optical lens 2802 may be used to provide different levels of optical magnification. In this example, for instance, the first lens portion 2812 may provide a specified amount of magnification (or possibly little or no magnification), and the second lens portion 2814 may provide a higher specified amount of magnification. In some embodiments, the second lens portion 2814 may represent a “full seg” of added magnification compared to the first lens portion 2812. Note that the amount of magnification provided by each of the lens portions 2812-2814 may or may not be based on any residual refractive error in a patient's eye. Also note that while the lens portion 2814 with additional magnification is placed at the bottom of the optical lens 2802, a lens portion with additional magnification may be placed in any other suitable location(s) or along any other suitable axis or axes of the optical lens 2802. Further note that the sizes and shapes of the lens portions 2812-2814 can vary as needed or desired.
As shown in
In this example, the haptics 3104 are formed by large projections that extend from the sides of the optical lens 3102, where the projections have a thickness that tapers towards the outer edges of the projections. This facilitates easier insertion of the haptics 3104 under the anterior leaflet of the capsular wall in a patient's eye. Each of the haptics 3104 could include a textured surface, such as a number of holes or other structures, that promotes confinement, capture, or attachment to the anterior leaflet of the capsular wall. While three haptics 3104 are shown here, other numbers and arrangements of haptics could also be used.
In this example, the optical lens 3102 of the intraocular pseudophakic contact lens 3100 includes a first lens portion 3112 and a second lens portion 3114. The two portions 3112-3114 of the optical lens 3102 may be used to provide different levels of optical magnification. In this example, for instance, the first lens portion 3112 may provide a specified amount of magnification (or possibly little or no magnification), and the second lens portion 3114 may provide a higher specified amount of magnification. Note that the amount of magnification provided by each of the lens portions 3112-3114 may or may not be based on any residual refractive error in a patient's eye. Also note that while the lens portion 3114 with additional magnification is placed in the center of the optical lens 3102, a lens portion with additional magnification may be placed in any other suitable location(s) or along any other suitable axis or axes of the optical lens 3102. Further note that the sizes and shapes of the lens portions 3112-3114 can vary as needed or desired.
As shown in
In this example, the haptics 3404 are formed by large projections that extend from the sides of the optical lens 3402, where the projections have a thickness that tapers towards the outer edges of the projections. This facilitates easier insertion of the haptics 3404 under the anterior leaflet of the capsular wall in a patient's eye. Each of the haptics 3404 could include a textured surface, such as a number of holes or other structures, that promotes confinement, capture, or attachment to the anterior leaflet of the capsular wall. While three haptics 3404 are shown here, other numbers and arrangements of haptics could also be used.
In this example, the optical lens 3402 of the intraocular pseudophakic contact lens 3400 includes a first lens portion 3412 and a second lens portion 3414. The two portions 3412-3414 of the optical lens 3402 may be used to provide different levels of optical magnification. In this example, for instance, the first lens portion 3412 may provide a specified amount of magnification (or possibly little or no magnification), and the second lens portion 3414 may provide a higher specified amount of magnification. In some embodiments, the second lens portion 3414 may represent a “small seg” of added magnification compared to the first lens portion 3412. Note that the amount of magnification provided by each of the lens portions 3412-3414 may or may not be based on any residual refractive error in a patient's eye. Also note that while the lens portion 3414 with additional magnification is placed near the bottom of the optical lens 3402, a lens portion with additional magnification may be placed in any other suitable location(s) or along any other suitable axis or axes of the optical lens 3402. Further note that the sizes and shapes of the lens portions 3412-3414 can vary as needed or desired.
While various prior approaches have secured an “add-on” lens to an intraocular lens, these prior approaches require a specific add-on lens to be designed for use with a specific intraocular lens and the specific intraocular lens to be designed for use with the specific add-on lens. That is, the add-on lens can only be used with a specific type of intraocular lens, where that intraocular lens is designed specifically for use with that add-on lens. As particular examples, an add-on lens may include haptics or other structures that are designed to mate with corresponding structures of specific intraocular lenses, or an intraocular lens may have a recess designed to receive a specific type of add-on lens. This can be problematic for a number of reasons. For instance, many patients already have existing intraocular lenses, and it may be impractical or even dangerous to try to remove those existing intraocular lenses in order to implant new intraocular lenses that are designed for use with add-on lenses.
The embodiments of the intraocular pseudophakic contact lenses shown in
Moreover, the intraocular pseudophakic contact lenses of
The various intraocular pseudophakic contact lenses described above could have any suitable size, shape, and dimensions. For example, the intraocular pseudophakic contact lenses could be made available in a range of diameters from about 4 mm to about 6 mm. Also, the intraocular pseudophakic contact lenses could be made available with varying base curvatures for their optical lenses. Of course, an intraocular pseudophakic contact lens could also be custom designed for a particular patient's eye, such as when one or more specific curvatures are needed to correct for residual refractive error or to provide other desired vision correction in the particular patient's eye.
The intraocular pseudophakic contact lenses disclosed here can be implanted non-invasively in patients' eyes and easily positioned on intraocular lenses. The implantation is non-invasive because an intraocular pseudophakic contact lens is being installed on the anterior surface of an intraocular lens, which is typically easily accessible by a surgeon or other personnel during an implantation procedure. The implantation is also non-invasive because the intraocular pseudophakic contact lenses can be attached to intraocular lenses without requiring attachment of the intraocular pseudophakic contact lenses to anatomical structures within the patients' eyes, such as to the suculus of a patient's eye.
The non-invasive implantation and easy positioning of an intraocular pseudophakic contact lens provide a safe and effective refractive surgical procedure to correct unwanted residual refractive error or provide some other desired vision correction, such as after a lensectomy procedure. As a refractive modality, the intraocular pseudophakic contact lenses contribute to a surgeon's ability to alter the current refractive error of a pseudophakic patient or otherwise alter the vision of the pseudophakic patient in an effort to adjust the patient's vision to achieve a finely-tuned desired refraction. Specific examples of this functionality include allowing adjustments to a patient's eye in order to achieve unilateral or bilateral emmetropia, to induce unilateral myopia to allow for intermediate and near visual function, to introduce multi-focality, and to treat unwanted residual astigmatism.
If the haptics of an intraocular pseudophakic contact lens include ridges along their bottom surfaces, the ridges can be used to center the intraocular pseudophakic contact lens on an underlying intraocular lens as described above. If the intraocular pseudophakic contact lens includes three haptics with associated ridges, the ridges could help to perfectly center the intraocular pseudophakic contact lens on the underlying intraocular lens. Such an approach allows the ridges of the intraocular pseudophakic contact lens' haptics to capture the underlying intraocular lens at the edge and perfectly line up the optical center of the intraocular pseudophakic contact lens' optic with the optical center of the intraocular lens. This alignment helps to reduce or avoid induced optical aberrations or induced prisms caused by optical center misalignment. This provides a strong contributing benefit over conventional refractive fine-tuning modalities.
Note that in any of the above examples, the intraocular pseudophakic contact lens could possibly be designed so that only the haptics of the intraocular pseudophakic contact lens extend under the anterior leaflet of the capsular wall in a patient's eye. This allows the haptics to be captured and confined by the anterior leaflet while leaving the optical lens of the intraocular pseudophakic contact lens free and generally unobscured by the surrounding tissue in the patient's eye.
Also note that, in some embodiments, the surgical tool disclosed in U.S. patent application Ser. No. 16/280,235 (which is hereby incorporated by reference in its entirety) may be used to help implant an intraocular pseudophakic contact lens. For example, this tool may be used to separate at least part of the anterior leaflet of a patient's eye from an implanted intraocular lens, allowing haptics of the intraocular pseudophakic contact lens to be inserted between the anterior leaflet and the intraocular lens. As another example, this tool may be used to separate the anterior leaflet of a patient's eye from an implanted intraocular pseudophakic contact lens, allowing the intraocular pseudophakic contact lens to be removed (and possibly replaced).
In addition, it should be appreciated from the description above that a wide variety of optical lenses or other optical devices may be used as the optical lens of any given intraocular pseudophakic contact lens. This enables intraocular pseudophakic contact lenses to be used to provide a wide variety of vision corrections in patients' eyes when joined with intraocular lenses in the patients' eyes. As noted above, for example, intraocular pseudophakic contact lenses may be used to help correct myopia, hyperopia, and/or astigmatism refractive errors in patients' eyes. As other examples, intraocular pseudophakic contact lenses may be used to provide magnification for low-vision patients, to provide guided focal points by way of adjusted prisms, and/or to provide variable apertures (such as pin holes, cat's eye structures, and/or stenopaeic slits). As other examples, intraocular pseudophakic contact lenses may be used to provide various forms of vision correction (such as multi-focal, astigmatic, depth of focus, asymmetrical cornea, and/or photochromic correction), to provide for drug delivery, to provide UV protection, and/or to support dysphotopsia treatment. In general, this disclosure is not limited to any specific types or shapes of optical lenses in intraocular pseudophakic contact lens or to any specific types of treatments using intraocular pseudophakic contact lens.
Although
The eye 3700 also includes a capsular bag 3708, which typically holds the natural crystalline lens of the eye 3700. However, in this example, the natural crystalline lens has been removed and replaced with an intraocular lens 3710 having an optical lens 3712 and one or more haptics 3714. The optical lens 3712 of the intraocular lens 3710 receives light entering the eye and focuses the light onto the retina of the eye 3700. The haptics 3714 of the intraocular lens 3710 help to hold the intraocular lens 3710 within the capsular bag 3708 so that the optical lens 3712 of the intraocular lens 3710 is in a desired position within the eye.
An intraocular pseudophakic contact lens 3716 has also been placed on the intraocular lens 3710 within the capsular bag 3708. The intraocular pseudophakic contact lens 3716 can represent any of the intraocular pseudophakic contact lenses described above or any other suitable intraocular pseudophakic contact lens. The intraocular pseudophakic contact lens 3716 is placed on the anterior surface of the intraocular lens 3710, meaning the front surface of the intraocular lens 3710 with respect to the eye 3700. Light enters through the cornea 3702 and passes through the pupil before entering the intraocular pseudophakic contact lens 3716, which modifies the light. The modified light then passes through the optical lens 3712 of the intraocular lens 3710 and is again modified. The twice-modified light then travels through the remainder of the eye 3700 to reach the retina at the back of the eye 3700.
As described above, the intraocular pseudophakic contact lens 3716 includes one or more haptics that extend a short distance and fit under an anterior leaflet 3718 of the capsular bag 3708. This allows the haptics to be captured and confined by the anterior leaflet 3718 (and possibly attach to the anterior leaflet 3718 via fibrosis or re-fibrosis). The anterior leaflet 3718 represents the outer portion of the front side of the capsular bag 3708 that remains after a capsulorhexis is formed in the capsular bag 3708. The insertion of the haptics of the intraocular pseudophakic contact lens 3716 under the anterior leaflet 3718 helps to secure the intraocular pseudophakic contact lens 3716 in place. In some cases, the healing process in the eye 3700 can cause fibrosis to occur, which could also attach the anterior leaflet 3718 to the haptics of the intraocular pseudophakic contact lens 3716.
Note that the haptics of the intraocular pseudophakic contact lens 3716 are shorter or smaller than the haptics 3714 of the intraocular lens 3710. This is because the haptics 3714 of the intraocular lens 3710 extend generally to the top and bottom of the capsular bag 3708 and help to hold the intraocular lens 3710 in the proper position within the capsular bag 3708. The haptics of the intraocular pseudophakic contact lens 3716 need not extend to the top and bottom of the capsular bag 3708 and instead may only extend a short distance under the anterior leaflet 3718.
By properly selecting the optical lens of the intraocular pseudophakic contact lens 3716, the intraocular pseudophakic contact lens 3716 can ideally correct any residual refractive error that remains after implantation of the intraocular lens 3710 or provide any other desired vision correction in the patient's eye 3700. If necessary, the intraocular pseudophakic contact lens 3716 can also be removed and replaced with a different intraocular pseudophakic contact lens. This may be needed or desired if the intraocular pseudophakic contact lens 3716 does not properly correct the residual refractive error, if the intraocular pseudophakic contact lens 3716 actually causes additional refractive errors, or if some other form of vision correction is needed or desired.
Although
An intraocular pseudophakic contact lens (IOPCL) is selected, such as to correct the identified residual refractive error or to provide some other form of vision correction, at step 3804. This could include, for example, personnel selecting an intraocular pseudophakic contact lens from a kit, where the selected intraocular pseudophakic contact lens has an optical lens that substantially neutralizes the identified residual refractive error. This could also include the personnel selecting an optical lens from a kit and inserting the optical lens into an intraocular pseudophakic contact lens, where the selected optical lens substantially cancels the identified residual refractive error. This could further include the personnel obtaining an intraocular pseudophakic contact lens having a custom-designed optical lens or obtaining a custom-designed optical lens for insertion into an intraocular pseudophakic contact lens, where the custom-designed optical lens substantially cancels the identified residual refractive error. In addition, this could include the personnel obtaining (in whatever manner) an intraocular pseudophakic contact lens that provides a desired amount of magnification, multi-focality, or other form of vision correction. In general, any mechanism can be used to obtain a suitable intraocular pseudophakic contact lens.
The selected intraocular pseudophakic contact lens is inserted into the patient's eye at step 3806. This could include, for example, a surgeon or other personnel forming a small incision in the patient's eye and inserting the intraocular pseudophakic contact lens into the eye through the incision. The intraocular pseudophakic contact lens can be rolled, folded, or otherwise reduced in cross-sectional size in order to insert the intraocular pseudophakic contact lens through a smaller incision.
One or more haptics of the intraocular pseudophakic contact lens are inserted under the anterior leaflet of the capsular wall in the patient's eye at step 3808. This could include, for example, the surgeon or other personnel placing the intraocular pseudophakic contact lens 3716 at a desired position (and possibly in a desired orientation) on the intraocular lens 3710. This could also include the surgeon or other personnel moving the intraocular pseudophakic contact lens 3716 so that its haptics (in whatever form) slide under the anterior leaflet 3718 of the capsular bag 3708.
A vision test for the patient occurs at step 3810. The vision test could be done in any suitable manner, such as by using intraoperative wavefront aberrometry. This vision test could also be performed at any suitable time, such as during the surgical procedure in which the intraocular pseudophakic contact lens is being implanted or after the surgical procedure has been completed. A determination is made whether the tested vision is satisfactory at step 3812. This could include, for example, personnel determining whether the patient's eye is still experiencing any residual refractive error and, if so, to what extent. This could also include personnel determining whether the patient's eye requires additional magnification, multi-focality, or other form of vision correction.
A determination is made whether to change the intraocular pseudophakic contact lens at step 3814. This could include, for example, the personnel and the patient determining whether the remaining residual refractive error (if any) is inconvenient or otherwise problematic for the patient or otherwise determining whether the current vision correction is inadequate. If so, different steps could be taken to try and fix the problem. For instance, the currently-implanted intraocular pseudophakic contact lens could be repositioned to adjust for cylinder axis correction. If that fails, another intraocular pseudophakic contact lens is selected at step 3816. This could include, for example, personnel selecting another intraocular pseudophakic contact lens that (ideally) provides a better refractive correction or other vision correction for the patient's eye compared to the currently-inserted intraocular pseudophakic contact lens. The currently-inserted intraocular pseudophakic contact lens is removed from the patient's eye at step 3818. This could include, for example, the surgeon or other personnel sliding the haptics of the currently-inserted intraocular pseudophakic contact lens 3716 from under the anterior leaflet 3718 and removing the currently-inserted intraocular pseudophakic contact lens 3716 from the patient's eye. The process then returns to step 3806, where the newly-selected intraocular pseudophakic contact lens can be inserted into the patient's eye and the vision test can be repeated.
After the process shown in
Although
It may be advantageous to set forth definitions of certain words and phrases used throughout this patent document. The terms “include” and “comprise,” as well as derivatives thereof, mean inclusion without limitation. The term “or” is inclusive, meaning and/or. The phrase “associated with,” as well as derivatives thereof, may mean to include, be included within, interconnect with, contain, be contained within, connect to or with, couple to or with, be communicable with, cooperate with, interleave, juxtapose, be proximate to, be bound to or with, have, have a property of, have a relationship to or with, or the like. The phrase “at least one of,” when used with a list of items, means that different combinations of one or more of the listed items may be used, and only one item in the list may be needed. For example, “at least one of: A, B, and C” includes any of the following combinations: A, B, C, A and B, A and C, B and C, and A and B and C.
The description in this patent document should not be read as implying that any particular element, step, or function is an essential or critical element that must be included in the claim scope. Also, none of the claims is intended to invoke 35 U.S.C. § 112(f) with respect to any of the appended claims or claim elements unless the exact words “means for” or “step for” are explicitly used in the particular claim, followed by a participle phrase identifying a function. Use of terms such as (but not limited to) “mechanism,” “module,” “device,” “unit,” “component,” “element,” “member,” “apparatus,” “machine,” “system,” “processor,” “processing device,” or “controller” within a claim is understood and intended to refer to structures known to those skilled in the relevant art, as further modified or enhanced by the features of the claims themselves, and is not intended to invoke 35 U.S.C. § 112(f).
While this disclosure has described certain embodiments and generally associated methods, alterations and permutations of these embodiments and methods will be apparent to those skilled in the art. Accordingly, the above description of example embodiments does not define or constrain this disclosure. Other changes, substitutions, and alterations are also possible without departing from the spirit and scope of this disclosure, as defined by the following claims.
This application is a continuation of U.S. patent application Ser. No. 16/717,304 filed on Dec. 17, 2019, which is a continuation-in-part of U.S. patent application Ser. No. 16/398,627 filed on Apr. 30, 2019 (now U.S. Pat. No. 10,945,832), which is a continuation-in-part of U.S. patent application Ser. No. 15/646,254 filed on Jul. 11, 2017 (now U.S. Pat. No. 10,299,910), which is a continuation-in-part of U.S. patent application Ser. No. 14/860,629 filed on Sep. 21, 2015 (now U.S. Pat. No. 10,159,562), which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 62/053,771 filed on Sep. 22, 2014. All of these applications are hereby incorporated by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4124905 | Clark | Nov 1978 | A |
| 5071432 | Baikoff | Dec 1991 | A |
| 5078742 | Dahan | Jan 1992 | A |
| 5098444 | Feaster | Mar 1992 | A |
| 5133747 | Feaster | Jul 1992 | A |
| 5201762 | Hauber | Apr 1993 | A |
| 5217491 | Vanderbilt | Jun 1993 | A |
| 5266241 | Parekh | Nov 1993 | A |
| 5275623 | Sarfarazi | Jan 1994 | A |
| 5354334 | Fedorov et al. | Oct 1994 | A |
| 5358520 | Patel | Oct 1994 | A |
| 5443506 | Garabet | Aug 1995 | A |
| 5443507 | Jacobi | Aug 1995 | A |
| 5522891 | Klaas | Jun 1996 | A |
| 5539016 | Kunzier et al. | Jul 1996 | A |
| 5684560 | Roffman et al. | Nov 1997 | A |
| 5693095 | Freeman et al. | Dec 1997 | A |
| 5699142 | Lee et al. | Dec 1997 | A |
| 5728156 | Gupta | Mar 1998 | A |
| 5755786 | Woffinden et al. | May 1998 | A |
| 5769890 | McDonald | Jun 1998 | A |
| 5782911 | Herrick | Jul 1998 | A |
| 5814103 | Lipshitz et al. | Sep 1998 | A |
| 5824074 | Koch | Oct 1998 | A |
| 6027531 | Tassignon | Feb 2000 | A |
| 6030416 | Huo et al. | Feb 2000 | A |
| 6045577 | Woffinden et al. | Apr 2000 | A |
| 6113633 | Portney | Sep 2000 | A |
| 6142625 | Sawano et al. | Nov 2000 | A |
| 6169127 | Lohmann et al. | Jan 2001 | B1 |
| 6197057 | Peyman et al. | Mar 2001 | B1 |
| 6200342 | Tassignon | Mar 2001 | B1 |
| 6217171 | Auten et al. | Apr 2001 | B1 |
| 6217612 | Woods | Apr 2001 | B1 |
| 6197058 | Portney | Jun 2001 | B1 |
| 6277146 | Peyman et al. | Aug 2001 | B1 |
| 6419697 | Kelman | Jul 2002 | B1 |
| 6454801 | Portney | Sep 2002 | B1 |
| 6464725 | Skotton | Oct 2002 | B2 |
| 6488708 | Sarfarazi | Dec 2002 | B2 |
| 6554859 | Lang et al. | Apr 2003 | B1 |
| 6554860 | Hoffmann et al. | Apr 2003 | B2 |
| 6558420 | Green | May 2003 | B2 |
| 6582076 | Roffman et al. | Jun 2003 | B1 |
| 6616691 | Tran | Sep 2003 | B1 |
| 6616692 | Glick et al. | Sep 2003 | B1 |
| 6645246 | Weinschenk, III et al. | Nov 2003 | B1 |
| 6705729 | Piers et al. | Mar 2004 | B2 |
| 6749634 | Hanna | Jun 2004 | B2 |
| 6767363 | Bandhauer et al. | Jul 2004 | B1 |
| 6797004 | Brady et al. | Sep 2004 | B1 |
| 6818017 | Shu | Nov 2004 | B1 |
| 6827738 | Willis et al. | Dec 2004 | B2 |
| 6851803 | Wooley et al. | Feb 2005 | B2 |
| 6860601 | Shadduck | Mar 2005 | B2 |
| 6880558 | Perez | Apr 2005 | B2 |
| 6926736 | Peng et al. | Aug 2005 | B2 |
| 6952313 | Schrader | Oct 2005 | B2 |
| 6960230 | Haefliger | Nov 2005 | B2 |
| 6960231 | Tran | Nov 2005 | B2 |
| 6991651 | Portney | Jan 2006 | B2 |
| 7008448 | Lipshitz et al. | Mar 2006 | B2 |
| 7008449 | Willis et al. | Mar 2006 | B2 |
| 7029497 | Zhang et al. | Apr 2006 | B2 |
| 7036931 | Lindacher et al. | May 2006 | B2 |
| 7081134 | Cukrowski | Jul 2006 | B2 |
| 7101397 | Aharoni | Sep 2006 | B2 |
| 7111938 | Andino et al. | Sep 2006 | B2 |
| 7118597 | Miller et al. | Oct 2006 | B2 |
| 7150760 | Zhang | Dec 2006 | B2 |
| 7186266 | Peyman | Mar 2007 | B2 |
| 7220278 | Peyman | May 2007 | B2 |
| 7223288 | Zhang et al. | May 2007 | B2 |
| 7238201 | Portney et al. | Jun 2007 | B2 |
| 7279006 | Vincent | Oct 2007 | B2 |
| 7311194 | Jin et al. | Dec 2007 | B2 |
| 7316713 | Zhang | Jan 2008 | B2 |
| 7338161 | Chauveau et al. | Mar 2008 | B2 |
| 7452378 | Zadno-Azizi et al. | Nov 2008 | B2 |
| 7453646 | Lo | Nov 2008 | B2 |
| 7462193 | Nagamoto | Dec 2008 | B2 |
| 7572007 | Simpson | Aug 2009 | B2 |
| 7591849 | Richardson | Sep 2009 | B2 |
| 7604349 | Blum et al. | Oct 2009 | B2 |
| 7744647 | Barrett | Jun 2010 | B2 |
| 7794498 | Pinchuk | Sep 2010 | B2 |
| 7806929 | Brown | Oct 2010 | B2 |
| 7842087 | Ben Nun | Nov 2010 | B2 |
| 7871162 | Weeber | Jan 2011 | B2 |
| 7871437 | Hermans et al. | Jan 2011 | B2 |
| 7875661 | Salamone | Jan 2011 | B2 |
| 7892264 | Sanders et al. | Feb 2011 | B2 |
| 7905917 | Altmann | Mar 2011 | B2 |
| 7918886 | Aharoni et al. | Apr 2011 | B2 |
| 7942929 | Linhardt et al. | May 2011 | B2 |
| 7955704 | Lowery et al. | Jun 2011 | B2 |
| 8012204 | Weinschenk, III et al. | Sep 2011 | B2 |
| 8034107 | Stenger | Oct 2011 | B2 |
| 8109999 | Hampp | Feb 2012 | B2 |
| 8133274 | Zhou et al. | Mar 2012 | B2 |
| 8197541 | Schedler | Jun 2012 | B2 |
| 8222360 | Liao | Jul 2012 | B2 |
| 8231219 | Weeber | Jul 2012 | B2 |
| 8273123 | Ben Nun | Sep 2012 | B2 |
| 8324256 | Domschke et al. | Dec 2012 | B2 |
| 8337552 | Kobayashi et al. | Dec 2012 | B2 |
| 8377124 | Hong et al. | Feb 2013 | B2 |
| 8419791 | Toop | Apr 2013 | B2 |
| 8430928 | Liao | Apr 2013 | B2 |
| 8491651 | Tsai et al. | Jul 2013 | B2 |
| 8523942 | Cumming | Sep 2013 | B2 |
| 8530590 | Hu et al. | Sep 2013 | B2 |
| 8579972 | Rombach | Nov 2013 | B2 |
| 8603167 | Rombach | Dec 2013 | B2 |
| 8608799 | Blake | Dec 2013 | B2 |
| 8636358 | Binder | Jan 2014 | B2 |
| 8680172 | Liao | Mar 2014 | B2 |
| 8696746 | Wanders et al. | Apr 2014 | B2 |
| 8834566 | Jones | Sep 2014 | B1 |
| 8852274 | Doraiswamy et al. | Oct 2014 | B2 |
| 8858626 | Noy | Oct 2014 | B2 |
| 8920495 | Mirlay | Dec 2014 | B2 |
| 8945213 | Terwee et al. | Feb 2015 | B2 |
| 8968399 | Ghabra | Mar 2015 | B2 |
| 8992611 | Zhao | Mar 2015 | B2 |
| D729390 | Doraiswamy et al. | May 2015 | S |
| 9039760 | Brady et al. | May 2015 | B2 |
| 9072600 | Tran | Jul 2015 | B2 |
| 9084674 | Brady et al. | Jul 2015 | B2 |
| D738947 | Litovchenko | Sep 2015 | S |
| 9237946 | Pynson | Jan 2016 | B2 |
| 9304329 | Zhao | Apr 2016 | B2 |
| 9329410 | Riall et al. | May 2016 | B2 |
| 9387069 | Kahook et al. | Jul 2016 | B2 |
| 9445892 | Brown | Sep 2016 | B2 |
| 9554893 | Brady et al. | Jan 2017 | B2 |
| 9675445 | Moriarty | Jun 2017 | B2 |
| 9757228 | Wanders et al. | Sep 2017 | B2 |
| 9808339 | Dorronsoro Diaz et al. | Nov 2017 | B2 |
| 9820849 | Jansen | Nov 2017 | B2 |
| 9848980 | McCafferty | Dec 2017 | B2 |
| 9869885 | De Sio et al. | Jan 2018 | B2 |
| 9931202 | Borja et al. | Apr 2018 | B2 |
| 9937034 | Wanders | Apr 2018 | B2 |
| 10004592 | Amon | Jun 2018 | B2 |
| 10004596 | Brady et al. | Jun 2018 | B2 |
| 10028824 | Kahook et al. | Jul 2018 | B2 |
| 10299910 | Cady | May 2019 | B2 |
| 10842614 | Cady | Nov 2020 | B2 |
| 11083622 | Cady et al. | Aug 2021 | B2 |
| 11109957 | Cady | Sep 2021 | B2 |
| 20020120329 | Lang et al. | Aug 2002 | A1 |
| 20020161436 | Portney | Oct 2002 | A1 |
| 20030158560 | Portney | Aug 2003 | A1 |
| 20030187504 | Weinschenk, III et al. | Oct 2003 | A1 |
| 20030220687 | Nordan et al. | Nov 2003 | A1 |
| 20040106993 | Portney | Jun 2004 | A1 |
| 20040158322 | Shen | Aug 2004 | A1 |
| 20040167621 | Peyman | Aug 2004 | A1 |
| 20040236422 | Zhang et al. | Nov 2004 | A1 |
| 20040249455 | Tran | Dec 2004 | A1 |
| 20050027354 | Brady et al. | Feb 2005 | A1 |
| 20050060032 | Magnante et al. | Mar 2005 | A1 |
| 20050113913 | Duvert | May 2005 | A1 |
| 20060001186 | Richardson et al. | Jan 2006 | A1 |
| 20060047339 | Brown | Mar 2006 | A1 |
| 20060058874 | Peli | Mar 2006 | A1 |
| 20060142856 | Willis et al. | Jun 2006 | A1 |
| 20060184244 | Nguyen et al. | Aug 2006 | A1 |
| 20060241752 | Israel | Oct 2006 | A1 |
| 20060253196 | Woods | Nov 2006 | A1 |
| 20060265059 | Sunada et al. | Nov 2006 | A1 |
| 20070010881 | Soye et al. | Jan 2007 | A1 |
| 20070016293 | Tran | Jan 2007 | A1 |
| 20070021832 | Nordan | Jan 2007 | A1 |
| 20070032866 | Portney | Feb 2007 | A1 |
| 20070118216 | Pynson | May 2007 | A1 |
| 20070260308 | Tran | Nov 2007 | A1 |
| 20070260309 | Richardson | Nov 2007 | A1 |
| 20070270947 | Peyman | Nov 2007 | A1 |
| 20070282438 | Hong et al. | Dec 2007 | A1 |
| 20080046077 | Cumming | Feb 2008 | A1 |
| 20080051886 | Lin | Feb 2008 | A1 |
| 20080086208 | Nordan | Apr 2008 | A1 |
| 20080103592 | Maloney | May 2008 | A1 |
| 20080147085 | Gardeski et al. | Jun 2008 | A1 |
| 20080208334 | Jinkerson et al. | Aug 2008 | A1 |
| 20080208335 | Blum | Aug 2008 | A1 |
| 20080215147 | Werblin | Sep 2008 | A1 |
| 20080281414 | Akahoshi | Nov 2008 | A1 |
| 20080288066 | Cumming | Nov 2008 | A1 |
| 20080312738 | Wanders | Dec 2008 | A1 |
| 20090048671 | Lipshitz et al. | Feb 2009 | A1 |
| 20090062911 | Bogaert | Mar 2009 | A1 |
| 20090130176 | Bossy-Nobs et al. | May 2009 | A1 |
| 20090182422 | Nordan et al. | Jul 2009 | A1 |
| 20090198326 | Zhou et al. | Aug 2009 | A1 |
| 20100004742 | Cumming | Jan 2010 | A1 |
| 20100016965 | Hong et al. | Jan 2010 | A1 |
| 20100036488 | de Juan, Jr. et al. | Feb 2010 | A1 |
| 20100094412 | Wensrich | Apr 2010 | A1 |
| 20100094413 | Rombach et al. | Apr 2010 | A1 |
| 20100131061 | Callahan et al. | May 2010 | A1 |
| 20100161048 | Schaper, Jr. | Jun 2010 | A1 |
| 20100161050 | Detmers et al. | Jun 2010 | A1 |
| 20100211171 | Sarfarazi | Aug 2010 | A1 |
| 20100280609 | Simonov et al. | Nov 2010 | A1 |
| 20100292789 | Willis et al. | Nov 2010 | A1 |
| 20110021733 | Wanders et al. | Jan 2011 | A1 |
| 20110153014 | Zhang et al. | Jun 2011 | A1 |
| 20110251686 | Masket | Oct 2011 | A1 |
| 20110313520 | Shoji et al. | Dec 2011 | A1 |
| 20110313521 | Angelopoulos | Dec 2011 | A1 |
| 20110313522 | Hayes | Dec 2011 | A1 |
| 20110313523 | Hayes | Dec 2011 | A1 |
| 20120109294 | Olson | May 2012 | A1 |
| 20120232649 | Cuevas | Sep 2012 | A1 |
| 20120253459 | Reich et al. | Oct 2012 | A1 |
| 20120323321 | Simonov et al. | Dec 2012 | A1 |
| 20130066422 | Dworschak et al. | Mar 2013 | A1 |
| 20130110234 | DeVita et al. | May 2013 | A1 |
| 20130110235 | Schwiegerling | May 2013 | A1 |
| 20130131796 | Mirlay | May 2013 | A1 |
| 20130190868 | Kahook et al. | Jul 2013 | A1 |
| 20130197636 | Haefliger | Aug 2013 | A1 |
| 20130204364 | Olson | Aug 2013 | A1 |
| 20130238091 | Danta et al. | Sep 2013 | A1 |
| 20130253159 | Benz et al. | Sep 2013 | A1 |
| 20130304206 | Pallikaris et al. | Nov 2013 | A1 |
| 20130317607 | Deboer et al. | Nov 2013 | A1 |
| 20130338767 | Mazzocchi et al. | Dec 2013 | A1 |
| 20140052246 | Kahook et al. | Feb 2014 | A1 |
| 20140058507 | Reich et al. | Feb 2014 | A1 |
| 20140121768 | Simpson | May 2014 | A1 |
| 20140180404 | Tran | Jun 2014 | A1 |
| 20140180406 | Simpson | Jun 2014 | A1 |
| 20140228949 | Argento et al. | Aug 2014 | A1 |
| 20140240657 | Pugh et al. | Aug 2014 | A1 |
| 20140243972 | Wanders | Aug 2014 | A1 |
| 20140253877 | Li et al. | Sep 2014 | A1 |
| 20140277434 | Weeber et al. | Sep 2014 | A1 |
| 20140330375 | McCafferty | Nov 2014 | A1 |
| 20140330376 | Kleinman | Nov 2014 | A1 |
| 20140347624 | Ando et al. | Nov 2014 | A1 |
| 20140368789 | Webb | Dec 2014 | A1 |
| 20150230981 | Kahook et al. | Aug 2015 | A1 |
| 20150297342 | Rosen et al. | Oct 2015 | A1 |
| 20160000558 | Honigsbaum | Jan 2016 | A1 |
| 20160008126 | Salahieh et al. | Jan 2016 | A1 |
| 20160081791 | Cady | Mar 2016 | A1 |
| 20160256265 | Borja et al. | Sep 2016 | A1 |
| 20160317286 | Brady et al. | Nov 2016 | A1 |
| 20160334643 | Hyde et al. | Nov 2016 | A1 |
| 20170172733 | Scharioth et al. | Jun 2017 | A1 |
| 20170296331 | Werblin et al. | Oct 2017 | A1 |
| 20170304045 | Cady | Oct 2017 | A1 |
| 20190254808 | Cady | Aug 2019 | A1 |
| 20200397562 | Cady | Dec 2020 | A1 |
| 20210186681 | Qureshi et al. | Jun 2021 | A1 |
| 20210282920 | Cady | Sep 2021 | A1 |
| 20210290369 | Cady | Sep 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 2014202532 | Jul 2014 | AU |
| PI1005015 | Apr 2013 | BR |
| 102012000755 | Oct 2013 | BR |
| 2717403 | Aug 2005 | CN |
| 201015617 | Feb 2008 | CN |
| 203425064 | Feb 2014 | CN |
| 19501444 | Jul 1996 | DE |
| 20109306 | Aug 2001 | DE |
| 10025320 | Nov 2001 | DE |
| 102007002885 | Jul 2008 | DE |
| 202010002895 | May 2010 | DE |
| 202013009162 | Nov 2013 | DE |
| 0760232 | Mar 1997 | EP |
| 1369710 | Dec 2003 | EP |
| 1449498 | Aug 2004 | EP |
| 1493405 | Jan 2005 | EP |
| 1504730 | Feb 2005 | EP |
| 1658828 | May 2006 | EP |
| 2666735 | Mar 1992 | FR |
| 2869793 | Nov 2005 | FR |
| 2966340 | Apr 2012 | FR |
| 2998474 | May 2014 | FR |
| 2464505 | Apr 2010 | GB |
| 2517531 | Feb 2015 | GB |
| H07255757 | Oct 1995 | JP |
| 2002360616 | Dec 2002 | JP |
| 4199573 | Oct 2004 | JP |
| 2006511242 | Apr 2006 | JP |
| 4363573 | Nov 2009 | JP |
| 4431372 | Mar 2010 | JP |
| 5398089 | Jun 2013 | JP |
| 5383782 | Jan 2014 | JP |
| 101555298 | Sep 2015 | KR |
| 2045246 | Oct 1995 | RU |
| 2080100 | Aug 1996 | RU |
| 2070004 | Dec 1996 | RU |
| 2129880 | May 1999 | RU |
| 2134086 | Aug 1999 | RU |
| 31954 | Sep 2003 | RU |
| 2234417 | Aug 2004 | RU |
| 47696 | Sep 2005 | RU |
| 2281063 | Aug 2006 | RU |
| 2281067 | Aug 2006 | RU |
| 2281726 | Aug 2006 | RU |
| 2283067 | Sep 2006 | RU |
| 2288494 | Nov 2006 | RU |
| 2377964 | Jan 2010 | RU |
| 2457811 | Aug 2012 | RU |
| 2479286 | Apr 2013 | RU |
| 2531472 | Oct 2014 | RU |
| M329428 | Apr 2008 | TW |
| 201103517 | Feb 2011 | TW |
| 9113597 | Sep 1991 | WO |
| 9215260 | Sep 1992 | WO |
| 9407435 | Apr 1994 | WO |
| 9413225 | Jun 1994 | WO |
| 9605047 | Feb 1996 | WO |
| 9712564 | Apr 1997 | WO |
| 9918457 | Apr 1999 | WO |
| 9935520 | Jul 1999 | WO |
| 9956671 | Nov 1999 | WO |
| 9962434 | Dec 1999 | WO |
| 0048491 | Aug 2000 | WO |
| 0108605 | Feb 2001 | WO |
| 0115635 | Mar 2001 | WO |
| 0187182 | Nov 2001 | WO |
| 2005104994 | Nov 2005 | WO |
| 2006025726 | Mar 2006 | WO |
| 2006119016 | Nov 2006 | WO |
| 2007138564 | Dec 2007 | WO |
| 2008094518 | Aug 2008 | WO |
| 2010131955 | Nov 2010 | WO |
| 2011115860 | Sep 2011 | WO |
| 2012054402 | Apr 2012 | WO |
| 2013055212 | Apr 2013 | WO |
| 2013169652 | Nov 2013 | WO |
| 2014058315 | Apr 2014 | WO |
| 2014058316 | Apr 2014 | WO |
| 2014071532 | May 2014 | WO |
| 2014099338 | Jun 2014 | WO |
| 2014108100 | Jul 2014 | WO |
| 2015006839 | Jan 2015 | WO |
| 2015022514 | Feb 2015 | WO |
| 2015026226 | Feb 2015 | WO |
| 2015037994 | Mar 2015 | WO |
| 2015044235 | Apr 2015 | WO |
| 2015066502 | May 2015 | WO |
| Entry |
|---|
| Grant of Patent dated Jan. 17, 2022 in connection with Korean Patent Application No. 10-2021-7018671, 7 pages. |
| International Search Report dated Feb. 17, 2021 in connection with International Patent Application No. PCT/US2020/61099, 3 pages. |
| Written Opinion of the International Searching Authority dated Feb. 17, 2021 in connection with International Patent Application No. PCT/US2020/61099, 6 pages. |
| Office Action dated Oct. 12, 2021 in connection with Mexican Patent Application No. MX/a/2017/003760, 7 pages. |
| Office Action dated Jan. 3, 2022 in connection with U.S. Appl. No. 17/011,975, 20 pages. |
| “1/1-DESIGNS-Questel”, May 2018, 3 pages. |
| “1/1-DESIGNS-Questel”, May 2018, 4 pages. |
| Extended European Search Report and Written Opinion for European Patent Application No. 15845158 dated Mar. 6, 2018, 9 pages. |
| International Search Report and Written Opinion of the International Searching Authority dated Aug. 30, 2018 in connection with International Patent Application No. PCT/US2018/36519, 13 pages. |
| International Search Report and Written Opinion of the International Searching Authority dated Dec. 21, 2015 in connection with International Patent Application No. PCT/US2015/051415, 9 pages. |
| Office Action dated Jun. 24, 2019 in connection with New Zealand Patent Application No. 729994, 3 pages. |
| Office Action dated Aug. 1, 2019 in connection with Japanese Patent Application No. 2017-535622, 11 pages. |
| Office Action in connection with Australian Patent Application No. 2019204613 dated Nov. 22, 2019, 3 pages. |
| Office Action dated Jul. 29, 2020 in connection with Australian Patent Application No. 2019204613, 3 pages. |
| Office Action dated May 20, 2020 in connection with Australian Patent Application No. 2018301248, 3 pages. |
| Communication pursuant to Article 94(3) EPC dated Jul. 15, 2020 in connection with European Patent Application No. 15845158.3, 6 pages. |
| Office Action dated Aug. 3, 2020 in connection with U.S. Appl. No. 16/398,627, 78 pages. |
| Supplementary European Search Report dated Oct. 28, 2020 in connection with European U.S. Appl. No. 18/831,320, 7 pages. |
| Communication pursuant to Rules 70(2) and 70a(2) EPC dated Nov. 17, 2020 in connection with European Patent Application No. 18831320, 1 page. |
| Office Action dated Jan. 5, 2021 in connection with Japanese Patent Application No. 2020-066515, 4 pages. |
| Office Action dated Mar. 19, 2020 in connection with U.S. Appl. No. 16/190,959, 81 pages. |
| Cady et al., “Intraocular Pseudophakic Contact Lens (IOPCL)-Based Telescopic Approach for Treating Age-Related Macular Degeneration (AMD) or Other Eye Disorders”, U.S. Appl. No. 17/332,533, filed May 27, 2021, 35 pages. |
| Examination Report dated Mar. 31, 2021 in connection with New Zealand Patent Application No. 755995, 3 pages. |
| Office Action dated Apr. 2, 2021 in connection with Chinese Patent Application No. 201880046413.X, 9 pages. |
| Notice of acceptance for patent application dated May 7, 2021 in connection with Australian Patent Application No. 2018301248, 31 pages. |
| Office Action dated Jul. 12, 2021 in connection with Australian Patent Application No. 2020239672, 4 pages. |
| European Search Report dated Jul. 16, 2021 in connection with European Patent Application No. 21161655.2, 5 pages. |
| Office Action dated Aug. 11, 2021 in connection with Australian Patent Application No. 2021200835, 2 pages. |
| Office Action dated Oct. 22, 2021 in connection with Canadian Patent Application No. 2,961,543, 5 pages. |
| Notice of Request for Submission of Argument dated Aug. 24, 2021 in connection with Korean Patent Application No. 10-2021-7018671, 12 pages. |
| European Search Report dated Sep. 2, 2021 in connection with European U.S. Appl. No. 21/168,724, 7 pages. |
| International Search Report and Written Opinion of the International Searching Authority dated Oct. 7, 2021 in connection with International Patent Application No. PCT/US2021/037911, 9 pages. |
| Japanese Patent Office, Office Action dated May 25, 2022 in connection with Japanese Patent Application No. 2021-085035, 4 pages. |
| Japanese Patent Office, Office Action dated Jul. 20, 2022 in connection with Japanese Patent Application No. 2020-501359, 4 pages. |
| Examination report No. 1 for standard Australian Patent Application No. 2021245264 dated Sep. 20, 2022, 4 pages. |
| Examination report No. 2 for standard Australian Patent Application No. 2021245264 dated Nov. 23, 2022, 3 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20210290370 A1 | Sep 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62053771 | Sep 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16717304 | Dec 2019 | US |
| Child | 17342246 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16398627 | Apr 2019 | US |
| Child | 16717304 | US | |
| Parent | 15646254 | Jul 2017 | US |
| Child | 16398627 | US | |
| Parent | 14860629 | Sep 2015 | US |
| Child | 15646254 | US |
